You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

  • Authors: Martine Piccart, MD, PhD; Fabrice Andre, MD, PhD; Giuseppe Curigliano, MD, PhD; Angelo DiLeo, MD, PhD; Luca Gianni, MD; Peter Schmid, FRCP, MD, PhD
  • CPD Released: 9/27/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/27/2018
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US healthcare professionals, specifically oncologists, obstetricians/gynecologists, and pathologists involved in the treatment of patients with hormone receptor-positive advanced breast cancer.

The goal of this activity is to improve physician knowledge regarding treatment options for patients with hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative, metastatic breast cancer (MBC).

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Clinical and pharmacological differences between cyclin-dependent kinase (CDK) 4/6 inhibitors
  • Mechanisms of resistance associated with CDK4/6 inhibitors
  • How CDK4/6 inhibitors work in different patient populations
  • Current evidence on the use of CDK4/6 inhibitors in clinical practice


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Martine Piccart, MD, PhD

    Jules Bordet Institute, Université Libre de Bruxelles; Chair, Breast International Group (BIG AISBL), Brussels, Belgium

    Disclosures

    Disclosure: Martine Piccart, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abraxis Oncology; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Roche
    Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc; Roche; Sanofi

  • Fabrice André, MD, PhD

    Professor of Medicine, Department of Medical Oncology, Université Paris Sud; Chairman, INSERM Unit U981, Institut Gustave Roussy, Villejuif, France

    Disclosures

    Disclosure: Fabrice André, MD, PhD, has disclosed the following relevant financial relationships:
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc

  • Giuseppe Curigliano, MD, PhD

    Professor, University of Milano; Head, European Institute of Oncology, Milan, Italy

    Disclosures

    Disclosure: Giuseppe Curigliano, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
    Served as a speaker or a member of a speakers bureau for: Pfizer Inc.; Roche

  • Angelo Di Leo, MD, PhD

    Head, Medical Oncology Unit; Chair, Oncology Department, "Sandro Pitigliani" Medical Oncology Unit - Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy

    Disclosures

    Disclosure: Angelo Di Leo, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Bayer HealthCare; Celgene Corporation; Daiichi Sankyo, Inc.; Eisai Co., Ltd; Genomic Health; Ipsen; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Pierre Fabre; Puma Biotechnology; Roche

  • Luca Gianni, MD

    Director, Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy

    Disclosures

    Disclosure: Luca Gianni, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ADC Therapeutics; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eli Lilly and Company; Genomic Health; Merck Sharp & Dohme Corp.; Odonate Therapeutics; Oncolytics Biotech Inc.; Onkaido; Pfizer Inc.; Roche; Sandoz; Seattle Genetics, Inc.; Synaffix; Synthon BV; Tahio Pharmaceutical

  • Peter Schmid, MD, PhD

    Professor, Centre for Experimental Cancer Medicine, St. Bartholomew Hospital; Chair of Cancer Medicine and Honorary Consultant in Medical Oncology Barts Cancer Institute, Queen Mary University London, London, United Kingdom

    Disclosures

    Disclosure: Peter Schmid, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Eisai Co., Ltd; Pfizer Inc; Puma Biotechnology

Editor

  • Deborah Middleton, MS

    Scientific Director, WebMD Global, LLC

    Disclosures

    Disclosure: Deborah Middleton, MS, has disclosed no relevant financial relationships.

Content Reviewer

  • Amy H. Seung, PharmD, BCOP

    Disclosures

    Disclosure: Amy H. Seung, PharmD, BCOP, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

CDK4/6 Inhibitors in Practice: Expert Insights and Perspectives

Authors: Martine Piccart, MD, PhD; Fabrice Andre, MD, PhD; Giuseppe Curigliano, MD, PhD; Angelo DiLeo, MD, PhD; Luca Gianni, MD; Peter Schmid, FRCP, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 9/27/2017

Valid for credit through: 9/27/2018

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

CDK4/6 Inhibitors in Practice: What Are the Differences?

Drs Piccart and Curigliano discuss the pharmacological and clinical differences between the 3 CDK4/6 inhibitors and the relevance of those differences in clinical practice.
Martine Piccart, MD, PhD; Giuseppe Curigliano, MD, PhD

CDK4/6 Inhibitors in Premenopausal Patients: What Is the Evidence?

Dr DiLeo discusses the use of CDK4/6 inhibitors in premenopausal patients.
Angelo DiLeo, MD, PhD

Impact of CDK4/6 Inhibitors on the Treatment Sequence: What Is the Evidence?

Dr Gianni discusses the topic of sequencing approaches with CDK4/6 inhibitors.
Luca Gianni, MD

Selecting the Right Endocrine Partner for CDK4/6 Inhibitors

Dr Schmid discusses the current data regarding endocrine therapy used in combination with CDK4/6 inhibitors.
Peter Schmid, FRCP, MD, PhD

Resistance to CDK4/6 Inhibitors: What Do We Know?

Dr Andre discusses the mechanisms of resistance associated with CDK4/6 inhibitors.
Fabrice Andre, MD, PhD

Educational Impact Challenge

The goal of this activity is to improve physician knowledge regarding treatment options for patients with hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative, metastatic breast cancer (MBC).

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.